News

May 27

2025

Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy

SAN DIEGO, May 27, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

May 5

2025

Phanes Therapeutics announces first patient dosed in clinical study of peluntamig in combination with atezolizumab

SAN DIEGO, May 5, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Feb 19

2025

Phanes Therapeutics announces first patient dosed in clinical study of peluntamig (PT217) in combination with chemotherapy

SAN DIEGO, Feb. 19, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Dec 4

2024

Phanes Therapeutics’ PT217 granted Fast Track designation by the FDA for NEPC

This is the second Fast Track Designation granted to PT217 by the agency SAN DIEGO, Dec. 4, 2024 /PRNewswire/ -- Phanes Therapeutics,...
Read More

Nov 6

2024

Phanes Therapeutics announces the appointment of gastrointestinal oncologist Prof. Zev Wainberg to its Clinical Advisory Board

SAN DIEGO, Nov. 5, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Oct 8

2024

Phanes Therapeutics announces first patient dosed in clinical study of PT886 in combination with KEYTRUDA® (pembrolizumab)

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Sep 9

2024

Phanes Therapeutics announces first patient dosed in clinical study of PT886 in combination with chemotherapy

SAN DIEGO, Sept. 9, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

Aug 16

2024

Phanes Therapeutics’ PT217 receives Orphan Drug designation for neuroendocrine carcinoma from the FDA

SAN DIEGO, Aug. 16, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and...
Read More

May 8

2024

Phanes Therapeutics, Inc. announces clinical supply agreement with Roche to evaluate PT217 in combination with an anti-PD-L1 therapy

PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibody The clinical supply agreement will focus on...
Read More

Apr 9

2024

Phanes Therapeutics’ PT217 granted Fast Track designation by the FDA

SAN DIEGO, April 8, 2024 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development...
Read More
1 2 3 5